If your email program has trouble displaying this email, view it as a web page

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FDA) approved the CyPass Micro-Stent in July 2016 for use in conjunction with cataract surgery in adult patients with mild-to-moderate primary open-angle glaucoma based on the results of the landmark two-year COMPASS study. ** If you did not subscribe to the FDA Recalls, Market Withdrawals and Safety Alerts subscription you may  unsubscribe from this list. For additional information pertaining to this message, please click the link at the beginning of this bulletin.

U.S. Food and Drug Administration 10903 New Hampshire Avenue, Silver Spring, MD 20993 1-888-INFO-FDA (1-888-463-6332) Privacy Policy | www.fda.gov Manage Preferences or Unsubscribe from this List | Unsubscribe from all Email Lists